Company: APM
Filing Date: 2025-12-05
Form Type: 424B5
Source: 0001213900-25-118752
Chunk: 428

Company: Aptorum Group Ltd
Filing Date: 2025-12-05
Form: 424B5
Chunk 428
---
, 2025. Unless
otherwise stated, the adjustments above do not have a recurring effect.

| (h) | Represents interest expense related to convertible notes to   
 be converted into shares of common stock of Aptorum Delaware. |

| (i) | Weighted average shares outstanding on a pro forma basis includes: |

| Aptorum Class A Ordinary Shares at June 30, 2025                           |     |  5,346,823 |
| Conversion of Aptorum Class B Ordinary Shares into common stock            |     |  1,796,934 |
| Conversion of note payable into common stock                               |     |  1,338,223 |
| Exercise of warrants                                                       |     |     54,054 |
| Conversion of Class A Ordinary Shares issued in Offering into common stock |     |  1,000,000 |
| Shares issued to DiamiR shareholders in merger                             |     | 19,917,413 |
| Warrants issuable for nominal consideration to Wainwright                  |     |    247,525 |
| Weighted Average Shares Outstanding – Basic and Diluted                    |     | 29,700,972 |

<div align='center'>247

I NDEX TO DIAMIR’S CONSOLIDATED FINANCIAL STATEMENTS</div>

|                                                                                                       |     | Page |
| Report of Independent Registered Public Accounting Firm (PCAOB 

# 199)                                 |     | F-2  |
| Report of Independent Registered Public Accounting Firm (PCAOB 

# 688)                                 |     | F-3  |
| Consolidated Balance Sheets as of May 31, 2025 and 2024                                               |     | F-4  |
| Consolidated Statements of Operations for the years ended May 31, 2025 and 2024                       |     | F-5  |
| Consolidated Statements of Changes in Stockholders’ Deficit for the years ended May 31, 2025 and 2024 |     | F-6  |
| Consolidated Statements of Cash Flows for the years ended May 31, 2025 and 2024                       |     | F-7  |
| Notes to Consolidated Financial Statements                                                            |     | F-8  |

<div align='center'>F-1

Report of Independent Registered Public Accounting Firm</div>

To the Stockholders and Board of Directors of

DiamiR Biosciences Corp.

Opinion on the Financial Statements

We have aud